PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.

Abstract Georgia, a country in the Caucasus region of Eurasia, has a high prevalence of hepatitis C virus (HCV) infection. In April 2015, with technical assistance from CDC, Georgia embarked on the world's first program to eliminate hepatitis C, defined as a 90% reduction in HCV prevalence by 2020 (1,2). The country committed to identifying infected persons and linking them to care and curative antiviral therapy, which was provided free of charge through a partnership with Gilead Sciences (1,2). From April 2015 through December 2016, a total of 27,595 persons initiated treatment for HCV infection, among whom 19,778 (71.7%) completed treatment. Among 6,366 persons tested for HCV RNA ≥12 weeks after completing treatment, 5,356 (84.1%) had no detectable virus in their blood, indicative of a sustained virologic response (SVR) and cure of HCV infection. The number of persons initiating treatment peaked in September 2016 at 4,595 and declined during October-December. Broader implementation of interventions that increase access to HCV testing, care, and treatment for persons living with HCV are needed for Georgia to reach national targets for the elimination of HCV.
PMID
Related Publications

Outcome of an optional HCV screening program for blood transfusion recipients in Ireland.

Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015.

Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.

National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.

Authors

Mayor MeshTerms

Disease Eradication

Mass Screening

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28749925
OWN - NLM
STAT- MEDLINE
DA  - 20170727
DCOM- 20170731
LR  - 20170731
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 29
DP  - 2017 Jul 28
TI  - The Role of Screening and Treatment in National Progress Toward Hepatitis C
      Elimination - Georgia, 2015-2016.
PG  - 773-776
LID - 10.15585/mmwr.mm6629a2 [doi]
AB  - Georgia, a country in the Caucasus region of Eurasia, has a high prevalence of
      hepatitis C virus (HCV) infection. In April 2015, with technical assistance from 
      CDC, Georgia embarked on the world's first program to eliminate hepatitis C,
      defined as a 90% reduction in HCV prevalence by 2020 (1,2). The country committed
      to identifying infected persons and linking them to care and curative antiviral
      therapy, which was provided free of charge through a partnership with Gilead
      Sciences (1,2). From April 2015 through December 2016, a total of 27,595 persons 
      initiated treatment for HCV infection, among whom 19,778 (71.7%) completed
      treatment. Among 6,366 persons tested for HCV RNA >/=12 weeks after completing
      treatment, 5,356 (84.1%) had no detectable virus in their blood, indicative of a 
      sustained virologic response (SVR) and cure of HCV infection. The number of
      persons initiating treatment peaked in September 2016 at 4,595 and declined
      during October-December. Broader implementation of interventions that increase
      access to HCV testing, care, and treatment for persons living with HCV are needed
      for Georgia to reach national targets for the elimination of HCV.
FAU - Nasrullah, Muazzam
AU  - Nasrullah M
FAU - Sergeenko, David
AU  - Sergeenko D
FAU - Gvinjilia, Lia
AU  - Gvinjilia L
FAU - Gamkrelidze, Amiran
AU  - Gamkrelidze A
FAU - Tsertsvadze, Tengiz
AU  - Tsertsvadze T
FAU - Butsashvili, Maia
AU  - Butsashvili M
FAU - Metreveli, David
AU  - Metreveli D
FAU - Sharvadze, Lali
AU  - Sharvadze L
FAU - Alkhazashvili, Maia
AU  - Alkhazashvili M
FAU - Shadaker, Shaun
AU  - Shadaker S
FAU - Ward, John W
AU  - Ward JW
FAU - Morgan, Juliette
AU  - Morgan J
FAU - Averhoff, Francisco
AU  - Averhoff F
LA  - eng
PT  - Journal Article
DEP - 20170728
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*therapeutic use
MH  - *Disease Eradication
MH  - Female
MH  - Georgia/epidemiology
MH  - Hepatitis C/epidemiology/*prevention & control
MH  - Humans
MH  - Male
MH  - *Mass Screening
MH  - Middle Aged
MH  - Prevalence
MH  - Program Evaluation
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2017/07/28 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/07/28 06:00
AID - 10.15585/mmwr.mm6629a2 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):773-776. doi:
      10.15585/mmwr.mm6629a2.